Exelixis logo

ExelixisNASDAQ: EXEL

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

17 April 2000

Next earnings report:

06 February 2025

Last dividends:

N/A

Next dividends:

N/A
$9.91 B
-4%vs. 3y high
93%vs. sector
-74%vs. 3y high
39%vs. sector
-3%vs. 3y high
78%vs. sector
-4%vs. 3y high
60%vs. sector

Price

regular market | 2 min ago
$34.71+$0.38(+1.11%)

Dividend

No data over the past 3 years
$539.54 M$561.68 M
$539.54 M$117.97 M

Analysts recommendations

Institutional Ownership

EXEL Latest News

3 Reasons Growth Investors Will Love Exelixis (EXEL)
zacks.com21 November 2024 Sentiment: -

Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.

EXEL vs. CSLLY: Which Stock Is the Better Value Option?
zacks.com21 November 2024 Sentiment: NEUTRAL

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents investors with the better value opportunity right now?

Looking for Earnings Beat? Buy These 4 Top-Ranked Stocks
zacks.com19 November 2024 Sentiment: POSITIVE

Top-ranked stocks Amazon.com (AMZN), Maplebear Inc. (CART), Exelixis (EXEL) and Doximity (DOCS) are likely to beat on the bottom line in their upcoming releases.

What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now?
zacks.com11 November 2024 Sentiment: POSITIVE

Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Exelixis (EXEL) is a Strong Momentum Stock
zacks.com11 November 2024 Sentiment: POSITIVE

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Exelixis (EXEL) is a Strong Value Stock
zacks.com07 November 2024 Sentiment: POSITIVE

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here is Why Growth Investors Should Buy Exelixis (EXEL) Now
zacks.com05 November 2024 Sentiment: POSITIVE

Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.

Earnings Estimates Rising for Exelixis (EXEL): Will It Gain?
zacks.com05 November 2024 Sentiment: POSITIVE

Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?
zacks.com05 November 2024 Sentiment: NEUTRAL

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two companies is the best option for those looking for undervalued stocks?

Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know
zacks.com04 November 2024 Sentiment: NEUTRAL

Explore how Exelixis' (EXEL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

What type of business is Exelixis?

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

What sector is Exelixis in?

Exelixis is in the Healthcare sector

What industry is Exelixis in?

Exelixis is in the Biotechnology industry

What country is Exelixis from?

Exelixis is headquartered in United States

When did Exelixis go public?

Exelixis initial public offering (IPO) was on 17 April 2000

What is Exelixis website?

https://www.exelixis.com

Is Exelixis in the S&P 500?

No, Exelixis is not included in the S&P 500 index

Is Exelixis in the NASDAQ 100?

No, Exelixis is not included in the NASDAQ 100 index

Is Exelixis in the Dow Jones?

No, Exelixis is not included in the Dow Jones index

When was Exelixis the previous earnings report?

No data

When does Exelixis earnings report?

The next expected earnings date for Exelixis is 06 February 2025